GeneDx Holdings Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
October 30, 2023 at 04:05 pm
Share
GeneDx Holdings Corp. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 53.3 million compared to USD 83.23 million a year ago. Net loss was USD 42.29 million compared to USD 77.58 million a year ago. Basic loss per share from continuing operations was USD 1.64 compared to USD 6.72 a year ago.
For the nine months, revenue was USD 145.15 million compared to USD 173.34 million a year ago. Net loss was USD 149.99 million compared to USD 240.22 million a year ago. Basic loss per share from continuing operations was USD 6.31 compared to USD 24.66 a year ago.
GeneDx Holdings Corp. is a genomics company. The Company is focused on delivering personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The Company's segments are GeneDx inclusive of Legacy GeneDx and Legacy Sema4. The GeneDx segment primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. GeneDx utilizes an integrated portfolio of laboratory processes, software tools, and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. GeneDx provides a variety of genetic diagnostic tests, screening solutions, and information. The Legacy Sema4 diagnostics segment provides reproductive and women's health and somatic oncology diagnostic testing and screening products.